Cover image for Vol. 121 Issue 14

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 4.889

ISI Journal Citation Reports © Ranking: 2014: 32/211 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians


  1. 1 - 100
  2. 101 - 128
  1. Correspondence

    1. Reply to the long and winding road in cancer survivorship care

      Aaron J. Dawes and Melinda Maggard-Gibbons

      Article first published online: 2 JUL 2015 | DOI: 10.1002/cncr.29546

    2. The long and winding road in cancer survivorship care

      Ernesto Zanet, Mariagrazia Michieli and Umberto Tirelli

      Article first published online: 2 JUL 2015 | DOI: 10.1002/cncr.29545

  2. Editorial

    1. Does one size fit all? The updated ovarian cancer staging: Still a work in progress

      Linda R. Duska and Elise C. Kohn

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29521

      The International Federation of Gynecology and Obstetrics (FIGO) has recognized serous tubal intraepithelial carcinoma as a precursor lesion for high-grade serous epithelial ovarian cancer. Future staging systems should consider reclassifying stage based on tumor biologic behavior.

  3. Review Articles

    1. Are we missing an opportunity for cancer prevention? Human papillomavirus vaccination for survivors of pediatric and young adult cancers

      Sarah M. Temkin and Nita L. Seibel

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29515

      Despite the risks of human papillomavirus–related disease, the uptake of human papillomavirus vaccination among childhood and adolescent cancer survivors has been low. The human papillomavirus vaccines are safe and effective, and increasing provider endorsements of vaccination in this population is important.

  4. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum

      Jaime Prat and for the FIGO Committee on Gynecologic Oncology

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29524

      The current article is an abridged version of the staging classification for cancer of the ovary, fallopian tube, and peritoneum, originally published in the International Journal of Gynecology and Obstetrics in January 2014.

    2. Discipline

      Disparities Research
      Racial differences in breast cancer survival in a large urban integrated health system

      Molly E. Roseland, Mary E. Pressler, Lois E. Lamerato, Rick Krajenta, Julie J. Ruterbusch, Jason C. Booza, Kendra Schwartz and Michael S. Simon

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29523

      Racial differences in breast cancer survival can be explained by clinical and socioeconomic factors. African American women with breast cancer remain disproportionately affected by unfavorable tumor characteristics and economic deprivation, which likely contribute to their increased overall mortality.

  5. Correspondence

    1. Reply to treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma

      Jessica N. Williams, Jean L. Koff and Christopher R. Flowers

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29508

      Reduced doses of R-CHOP, non-anthracycline-based regimens, and non-pegylated liposomal doxorubicin are potential alternative regimens for elderly patients with diffuse large B-cell lymphoma who cannot tolerate standard R-CHOP. Radiation therapy with abbreviated R-CHOP should also be further investigated as a treatment option in this population.

  6. Original Articles

    1. Discipline

      Clinical Trials
      A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)

      Gunter von Minckwitz, Bettina Conrad, Toralf Reimer, Thomas Decker, Holger Eidtmann, Wolfgang Eiermann, John Hackmann, Volker Möbus, Frederik Marmé, Jochem Potenberg, Elmar Stickeler, Eike Simon, Christoph Thomssen, Jens Huober, Carsten Denkert, Joachim Alfer, Christian Jackisch, Valentina Nekljudova, Nicole Burchardi, Sibylle Loibl and for the German Breast Group Investigators

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29506

      The results of the ICE II (Investigational Chemotherapy for Elderly patients trial II) trial demonstrated that nonfrail elderly patients with moderate or high-risk breast cancer can be treated with taxane-based polychemotherapy. However, compound-specific toxicities appear to lower relative dose intensity and therefore potential survival benefits.

  7. Correspondence

  8. Original Articles

    1. Discipline

      Folate-mediated one-carbon metabolism genes and interactions with nutritional factors on colorectal cancer risk: Women's Health Initiative Observational Study

      Ting-Yuan David Cheng, Karen W. Makar, Marian L. Neuhouser, Joshua W. Miller, Xiaoling Song, Elissa C. Brown, Shirley A. A. Beresford, Yingye Zheng, Elizabeth M. Poole, Rachel L. Galbraith, David J. Duggan, Nina Habermann, Lynn B. Bailey, David R. Maneval, Marie A. Caudill, Adetunji T. Toriola, Ralph Green and Cornelia M. Ulrich

      Article first published online: 24 JUN 2015 | DOI: 10.1002/cncr.29465

      Evidence from genetic variants suggests that one-carbon metabolism is associated with colorectal cancer risk in postmenopausal women. The essential nutrients in the metabolism (ie, folate, vitamin B6, and vitamin B12) continue to emerge as effect modifiers of genetic influences on colorectal cancer risk.

  9. Commentary

    1. Are high drug prices for hematologic malignancies justified? A critical analysis

      Jagpreet Chhatwal, Michael Mathisen and Hagop Kantarjian

      Article first published online: 23 JUN 2015 | DOI: 10.1002/cncr.29512

      Twenty-nine cost-effectiveness analyses of the treatment of hematologic malignancies published from 1996 to 2012 are evaluated. The current costs of the majority of treatments for hematologic cancers are too high to be deemed cost-effective in the United States.

  10. Original Articles

    1. Discipline

      Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States

      Susan Hariri, Michelle L. Johnson, Nancy M. Bennett, Heidi M. Bauer, Ina U. Park, Sean Schafer, Linda M. Niccolai, Elizabeth R. Unger, Lauri E. Markowitz and HPV-IMPACT Working Group

      Article first published online: 22 JUN 2015 | DOI: 10.1002/cncr.29266

      Significant declines in high-grade cervical lesions in young women since 2008 are likely due to reduced cervical cancer screening but could also reflect vaccine impact. See also pages 000-000.

  11. Editorial

    1. Trends in cervical intraepithelial neoplasia Grade 2+ after human papillomavirus vaccination: The devil is in the details

      Harinder Brar and Allan Covens

      Article first published online: 22 JUN 2015 | DOI: 10.1002/cncr.29264

      Eight years since the introduction of the adolescent HPV vaccination programs, as the vaccinated cohort enters adulthood, the impact of these vaccination programs is now being assessed through surrogate markers such as the incidence of high-grade cervical dysplasia (cytology/histology) and the incidence of genital warts. Early data from the HPV-IMPACT study shows that although there has been a noticeable drop in CIN2+ incidence rates, the results may be confounded by the recent changes in cervical screening guidelines. This study is significant in that it is the first to report on changes in high-grade histological abnormalities in the postvaccination era. Despite the confounding effect of changing cervical cancer screening guidelines, the findings cannot be completely ignored. With wider acceptance and standardization of cervical cancer screening guidelines and with an increasing number of women entering the vaccinated cohort, the magnitude of vaccine effectiveness should become more obvious. Further studies are needed to assess the changes in high-grade histological abnormalities in the post-vaccine era.

  12. Erratum

    1. You have free access to this content
  13. Original Articles

    1. Disease Site

      Breast Disease
      Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial

      Jiayu Wang, Binghe Xu, Peng Yuan, Fei Ma, Qing Li, Pin Zhang, Ruigang Cai, Ying Fan, Yang Luo and Qiao Li

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29492

      The median progression-free survival and duration of response are longer in patients with advanced breast cancer who receive combined docetaxel and capecitabine chemotherapy compared with those who receive combined vinorelbine and capecitabine. Hand-foot syndrome occurs more frequently in the docetaxel/capecitabine group.

    2. Hematologic Malignancies
      Characteristics of primary splenic diffuse large B-cell lymphoma and role of splenectomy in improving survival

      Osnat Bairey, Lev Shvidel, Chava Perry, Eldad J. Dann, Rosa Ruchlemer, Tamar Tadmor and Neta Goldschmidt

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29487

      Primary splenic diffuse large B-cell lymphoma generally presents with abdominal pain, high lactose dehydrogenase levels, and a splenic mass. Splenectomy at diagnosis improves progression-free and overall survival for patients with early-stage disease.

  14. Editorial

    1. Radiofrequency ablation in high-risk stage I non–small cell lung cancer

      Jessica S. Donington

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29501

      Dupuy et al demonstrate excellent safety, tolerability, and preservation of pulmonary function in this multi-institutional, prospective evaluation of radiofrequency ablation for medically unresectable non–small cell lung cancer. Unfortunately, the rate of local recurrence is 40% at 2 years, and this decreases some enthusiasm for its use in patients who have a radiation or surgical option.

  15. Original Articles

    1. Discipline

      Clinical Trials
      Radiofrequency ablation of stage IA non–small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial

      Damian E. Dupuy, Hiran C. Fernando, Shauna Hillman, Thomas Ng, Angelina D. Tan, Amita Sharma, William S. Rilling, Kelvin Hong and Joe B. Putnam

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29507

      This highly controlled, National Cancer Institute–funded, multicenter trial shows that radiofrequency ablation can provide safe and effective treatment for patients with medically inoperable early-stage non–small cell lung cancer in a single outpatient session. Thermal ablation should continue to play a role in medically inoperable patients with lung cancer and perhaps in high-risk operable patients currently treated with sublobar resection.

    2. Psychosocial Oncology
      Parenting changes in adults with cancer

      Cynthia W. Moore, Paula K. Rauch, Lee Baer, William F. Pirl and Anna C. Muriel

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29525

      Declines in parenting self-efficacy beliefs after a cancer diagnosis are correlated to aspects of treatment, health-related quality of life, depression and distress, and concerns about the impact of cancer on dependent children. This study highlights the importance of both identifying parenting concerns as a potential mediator between parental cancer and children's heightened risk for psychosocial difficulties and addressing these concerns to alleviate patient distress.

    3. Disease Site

      Head and Neck Disease
      Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer

      Kristina R. Dahlstrom, Guojun Li, Caroline S. Hussey, Jenny T. Vo, Qingyi Wei, Chong Zhao and Erich M. Sturgis

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29538

      Circulating human papillomavirus (HPV) DNA has been detected in patients with carcinoma of the oropharynx. Progression-free survival appears to be better among patients with pretreatment HPV DNA in their tumors and among patients with HPV-positive tumors who are negative for pretreatment serum HPV DNA compared with patients whose tumors are negative for HPV and those whose tumors are positive for HPV who were positive for pretreatment serum HPV DNA, respectively. Circulating HPV DNA does not appear to have clinical usefulness as a marker for disease recurrence in patients with oropharyngeal carcinoma.

  16. Listen to the Patient

    1. Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer

      Yuhree Kim, Megan Winner, Andrew Page, Diana M. Tisnado, Kathryn A. Martinez, Stefan Buettner, Aslam Ejaz, Gaya Spolverato, Sydney E. Morss Dy and Timothy M. Pawlik

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29530

      The objective of the current study was to characterize the prevalence of the expectation that surgical resection of lung or colorectal cancer might be curative. The overwhelming majority of patients undergoing surgery for lung or colorectal cancer believe that the surgery is likely to be curative, even among those patients with advanced stage IV disease. Greater focus on patient-physician engagement, communication, and barriers to discussing goals of care with patients diagnosed with cancer is needed.

  17. Review Articles

    1. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis

      Darrick K. Li and Raymond T. Chung

      Article first published online: 16 JUN 2015 | DOI: 10.1002/cncr.29528

      The rise of direct-acting antivirals heralds an incipient revolution in hepatitis C virus treatment with increasing sustained virological response rates and reductions in hepatitis C virus–associated hepatocellular carcinoma. Epidemiologic and genetic studies are identifying a subpopulation of sustained virological response patients who remain at risk for hepatocellular carcinoma development and would benefit from continued screening.

  18. Original Articles

    1. Disease Site

      Hematologic Malignancies
      A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

      Timothy S. Fenske, Namrata M. Shah, Kyung Mann Kim, Sandeep Saha, Chong Zhang, Arielle E. Baim, John P. Farnen, Adedayo A. Onitilo, Jules H. Blank, Harish Ahuja, Tim Wassenaar, Rubina Qamar, Patrick Mansky, Anne M. Traynor, Ryan J. Mattison and Brad S. Kahl

      Article first published online: 16 JUN 2015 | DOI: 10.1002/cncr.29502

      The combination of bortezomib and temsirolimus demonstrates activity in patients with previously treated relapsed/ refractory B-cell non-Hodgkin lymphoma. An overall response rate of 31% was seen, including complete remissions in two heavily pre-treated patients with diffuse large B-cell lymphoma.

    2. Discipline

      Quality of Life
      Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials

      Fabio Efficace, Peter Fayers, Andrea Pusic, Yeliz Cemal, Jane Yanagawa, Marc Jacobs, Andrea la Sala, Valentina Cafaro, Katie Whale, Jonathan Rees, Jane Blazeby and for the European Organization for Research and Treatment of Cancer Quality-of-Life Group (Patient-Reported Outcome Measurements Over Time in Oncology Registry)

      Article first published online: 16 JUN 2015 | DOI: 10.1002/cncr.29489

      Five hundred fifty-seven randomized controlled trials with a patient-reported outcome endpoint have been conducted across several cancer specialties within a decade. Overall, the quality of reporting is generally poor according to the Consolidated Standards of Reporting Trials patient-reported outcome extension; however, reporting is higher in randomized controlled trials with a patient-reported outcome as a primary endpoint.

  19. Correspondence

    1. Reply to discrepancies in drug approvals: A global dilemma

      Doreen A. Ezeife, Tony H. Truong and Patricia A. Tang

      Article first published online: 16 JUN 2015 | DOI: 10.1002/cncr.29482

    2. Discrepancies in drug approvals: A global dilemma

      Michelle K. Wilson, Katherine Karakasis and Amit M. Oza

      Article first published online: 16 JUN 2015 | DOI: 10.1002/cncr.29484

  20. Original Articles

    1. Discipline

      Outcomes Research
      Trends in surveillance for resected colorectal cancer, 2001-2009

      E. Carter Paulson, Christine M. Veenstra, Anil Vachani, Christine A. Ciunci and Andrew J. Epstein

      Article first published online: 16 JUN 2015 | DOI: 10.1002/cncr.29469

      There continues to be substantial underuse of guideline-recommended surveillance for stage III and high-risk stage II colorectal cancer survivors, whereas many stage I patients receive intensive surveillance despite an absence of supporting evidence. The 2005 inclusion of computed tomography imaging in the surveillance guidelines has had a negligible impact on computed tomography surveillance in colorectal cancer survivors.

  21. Correspondence

  22. Review Articles

    1. You have full text access to this OnlineOpen article
      Ovarian cancer treatment: The end of empiricism?

      Stephanie Lheureux, Katherine Karakasis, Elise C. Kohn and Amit M. Oza

      Article first published online: 10 JUN 2015 | DOI: 10.1002/cncr.29481

      The authors discuss the current understanding of the biology of the ovarian cancer, diagnostic and treatment strategies, and high-priority directions for investigation.

  23. Original Articles

    1. Discipline

      Psychosocial Oncology
      Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer

      Lauren Z. Davis, George M. Slavich, Premal H. Thaker, Michael J. Goodheart, David P. Bender, Laila Dahmoush, Donna M. Farley, Kristian E. Markon, Frank J. Penedo, David M. Lubaroff, Steve W. Cole, Anil K. Sood and Susan K. Lutgendorf

      Article first published online: 10 JUN 2015 | DOI: 10.1002/cncr.29516

      Psychosocial factors may be related to sympathetic nervous system activation, with implications for tumor progression in patients with ovarian cancer. The results of the current study indicate that eudaimonic well-being is related to lower tumor norepinephrine in patients with ovarian cancer whereas positive affect and psychological distress are not.

    2. Disease Site

      Chest and Lung Disease
      Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

      Jarushka Naidoo, Camelia S. Sima, Katherine Rodriguez, Natalie Busby, Khedoudja Nafa, Marc Ladanyi, Gregory J. Riely, Mark G. Kris, Maria E. Arcila and Helena A. Yu

      Article first published online: 10 JUN 2015 | DOI: 10.1002/cncr.29493

      Epidermal growth factor receptor (EGFR) exon 20 insertions are harbored in 2% of metastatic lung adenocarcinomas, and patients with these tumors have similar survival compared to patients whose tumors harbor sensitizing EGFR mutations. The majority of EGFR exon 20 insertion variants impart resistance to EGFR tyrosine kinase inhibitors.

  24. Review Articles

    1. Immunotherapy in acute myeloid leukemia

      Dolores A. Grosso, Rosemary C. Hess and Mark A. Weiss

      Article first published online: 10 JUN 2015 | DOI: 10.1002/cncr.29378

      The authors review immunologic strategies that have been used in the treatment of acute myeloid leukemia. Areas addressed include transplantation and nontransplantation immunologic approaches to acute myeloid leukemia treatment as well as newer therapies, such as chimeric antigen receptors and bispecific T-cell engagers.

  25. Original Articles

    1. Disease Site

      Genitourinary Disease
      Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma

      M. Dror Michaelson, Rana R. McKay, Lillian Werner, Michael B. Atkins, Eliezer M. Van Allen, Kara M. Olivier, Jiaxi Song, Sabina Signoretti, David F. McDermott and Toni K. Choueiri

      Article first published online: 8 JUN 2015 | DOI: 10.1002/cncr.29503

      This study demonstrates that multimodality therapy with gemcitabine and sunitinib is feasible and is associated with objective responses in patients with sarcomatoid or poor-risk renal cell carcinoma. The results of this study are currently being validated in a randomized phase 2 trial of sunitinib with or without gemcitabine for advanced sarcomatoid renal cell carcinoma (NCT01164228).

    2. Discipline

      Outcomes Research
      Disparities in survival by insurance status in patients with Hodgkin lymphoma

      Rahul R. Parikh, Michael L. Grossbard, B. Lee Green, Louis B. Harrison and Joachim Yahalom

      Article first published online: 8 JUN 2015 | DOI: 10.1002/cncr.29518

      Unfavorably insured patients with Hodgkin lymphoma appear to have limited access to care. Significant disparities in outcomes have been identified for patients with unfavorable insurance.

    3. Disease Site

      Gastrointestinal Disease
      Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice

      Anne-Sophie Dussol, Marie-Odile Joly, Cecile Vercherat, Julien Forestier, Valérie Hervieu, Jean-Yves Scoazec, Catherine Lombard-Bohas and Thomas Walter

      Article first published online: 8 JUN 2015 | DOI: 10.1002/cncr.29517

      This study reports the activity of gemcitabine and oxaliplatin in neuroendocrine tumors. The outcomes are similar to those with alkylating agents, but the O6-methylguanine-DNA methyltransferase status has no influence.

  26. Correspondence

  27. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      Heat shock protein 60 levels in tissue and circulating exosomes in human large bowel cancer before and after ablative surgery

      Claudia Campanella, Francesca Rappa, Carmelo Sciumè, Antonella Marino Gammazza, Rosario Barone, Fabio Bucchieri, Sabrina David, Giuseppe Curcurù, Celeste Caruso Bavisotto, Alessandro Pitruzzella, Girolamo Geraci, Giuseppe Modica, Felicia Farina, Giovanni Zummo, Stefano Fais, Everly Conway de Macario, Alberto J.L. Macario and Francesco Cappello

      Article first published online: 8 JUN 2015 | DOI: 10.1002/cncr.29499

      Heat shock protein 60 is a chaperonin involved in tumorigenesis but its participation in tumor development and progression is not well understood and its value as a tumor biomarker has not been fully elucidated. In the current study, the authors present evidence supporting the theory that heat shock protein 60 has potential as biomarker as well as a therapeutic target in patients with colon cancer.

    2. Discipline

      Symptom Control and Palliative Care
      Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: A prospective, multicenter study

      David Hui, Omar Shamieh, Carlos Eduardo Paiva, Pedro Emilio Perez-Cruz, Jung Hye Kwon, Mary Ann Muckaden, Minjeong Park, Sriram Yennu, Jung Hun Kang and Eduardo Bruera

      Article first published online: 8 JUN 2015 | DOI: 10.1002/cncr.29437

      When a symptom response is being assessed, how much of a change on a 0- to 10-point numeric rating scale is considered clinically significant? In this multicenter, prospective, longitudinal study involving 796 patients with advanced cancer, the minimal clinically important difference is universally a 1-point difference for both improvement and deterioration for each of the 10 symptoms in the Edmonton Symptom Assessment Scale, one of the most widely used symptom assessment batteries in oncology.

    3. Variation in symptom distress in underserved Chinese American cancer patients

      Lara K. Dhingra, Kin Lam, William Cheung, Theresa Shao, Zujun Li, Sandra Van de Maele, Victor T. Chang, Jack Chen, Huiyan Ye, Rhoda Wong, Wan Ling Lam, Selina Chan, Marilyn Bookbinder, Nathan F. Dieckmann and Russell Portenoy

      Article first published online: 8 JUN 2015 | DOI: 10.1002/cncr.29497

      In a large sample of community-dwelling Chinese American cancer patients, symptom prevalence has been found to be high, and clinically relevant subgroups with different profiles of symptom distress can be identified. These data may inform patient management and improve disparities in care.

    4. Medical Oncology
      Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues

      Bertrand Brieau, Laetitia Dahan, Yann De Rycke, Tarek Boussaha, Philippe Vasseur, David Tougeron, Thierry Lecomte, Romain Coriat, Jean-Baptiste Bachet, Pierre Claudez, Aziz Zaanan, Pauline Soibinet, Jérome Desrame, Anne Thirot-Bidault, Isabelle Trouilloud, Florence Mary, Lysiane Marthey, Julien Taieb, Wulfran Cacheux and Astrid Lièvre

      Article first published online: 5 JUN 2015 | DOI: 10.1002/cncr.29471

      Second-line chemotherapy for advanced biliary tract cancer may provide disease control in select patients, but the prognosis remains poor, and no particular regimen seems superior to others. Good performance status and disease control by the first-line treatment are both associated with longer survival.

  28. Review Articles

    1. The importance of assessing priorities of reproductive health concerns among adolescent and young adult patients with cancer

      Devin Murphy, James L. Klosky, Damon R. Reed, Amanda M. Termuhlen, Susan V. Shannon and Gwendolyn P. Quinn

      Article first published online: 5 JUN 2015 | DOI: 10.1002/cncr.29466

      Adolescent and young adult cancer survivors consistently indicate that reproductive health is of great importance and deserves more attention. However, there is a deficiency in the adolescent and young adult literature with regard to which concerns take priority, and the most effective approach for communicating reproductive health information between patients and their families and health care providers.

  29. Original Articles

    1. Discipline

      Radiation Oncology
      What is the optimal management of early-stage low-grade follicular lymphoma in the modern era?

      John A. Vargo, Beant S. Gill, Goundappa K. Balasubramani and Sushil Beriwal

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29491

      In what to the authors' knowledge is the largest outcomes analysis for early-stage low-grade follicular lymphoma with over 35,000 patients spanning a 14-year period from 1998 through 2012, radiotherapy use continues to decline in favor of alternative treatment strategies, most notably observation without initial treatment and single-agent chemotherapy. This concerning decline is coupled with findings of improved overall survival in patients receiving radiotherapy, either alone or in conjunction with systemic therapy, even after adjusting for indication bias.

  30. Erratum

    1. You have free access to this content
  31. Original Articles

    1. Discipline

      Psychosocial Oncology
      The lasting impact of the therapeutic alliance: Patient-oncologist alliance as a predictor of caregiver bereavement adjustment

      Kelly M. Trevino, Paul K. Maciejewski, Andrew S. Epstein and Holly G. Prigerson

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29505

      Cancer patients’ perceptions of a strong therapeutic alliance with their oncologist predict better caregiver mental health 6 months after the patient's death based on caregivers’ self-report and interviewers’ postloss rating. By developing a strong relationship with the patient, the oncologist may benefit the caregiver in addition to the patient.

  32. Review Articles

    1. The mu opioid receptor: A new target for cancer therapy?

      Patrick A. Singleton, Jonathan Moss, Daniel D. Karp, Johnique T. Atkins and Filip Janku

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29460

      In this review, the authors present preclinical and clinical data that support their hypothesis that the mu opioid receptor is a potential target for cancer therapy because of its plausible role in tumor progression. The authors also propose the hypothesis that peripheral opioid antagonists such as methylnaltrexone, which reverses the peripheral effects of mu opioids but maintains centrally mediated analgesia and is approved by the US Food and Drug Administration to treat opioid-induced constipation, can be used to target the mu opioid receptor.

  33. Editorial

    1. Coordination of care in colon cancer

      George J. Chang and Scott Kopetz

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29473

      Solutions to the problem of a “system in crisis” for cancer care delivery should be of the highest priority for academics, policymakers, providers, patient advocacy organizations, and funding agencies alike. Although programs such as the Affordable Care Act emphasize the principles of coordinated and patient-centered care to improve outcomes and value, real-world examples such as the current study help to shed light on how the principles may be implemented to improve the delivery of cancer care.

  34. Original Articles

    1. Discipline

      Outcomes Research
      Fragmentation in specialist care and stage III colon cancer

      Tanvir Hussain, Hsien-Yen Chang, Christine M. Veenstra and Craig Evan Pollack

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29474

      A significant proportion of colon cancer patients receive surgical and medical oncology care fragmented across more than 1 hospital. This fragmentation increases costs but may not affect survival.

    2. Disease Site

      Hematologic Malignancies
      Monosomal karyotype predicts inferior survival independently of a complex karyotype in patients with myelodysplastic syndromes

      Zoe K. McQuilten, Vijaya Sundararajan, Nick Andrianopoulos, David J. Curtis, Erica M. Wood, Lynda J. Campbell and Meaghan Wall

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29396

      A monosomal karyotype is an independent predictor of a poor prognosis for patients with myelodysplastic syndromes. The prognostic utility of a monosomal karyotype is independent of a complex karyotype.

    3. Discipline

      Radiation Oncology
      Combined intensity-modulated radiotherapy plus raster-scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival

      Alexandra D. Jensen, Anna V. Nikoghosyan, Melanie Poulakis, Angelika Höss, Thomas Haberer, Oliver Jäkel, Marc W Münter, Daniela Schulz-Ertner, Peter E. Huber and Jürgen Debus

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29443

      Patients with adenoid cystic carcinoma (ACC) of the head and neck who receive intensity-modulated radiotherapy plus carbon ion boost (C12 therapy) at a biologically effective dose of 80 Gray using modern photon techniques achieve superior locoregional control and overall survival rates compared with those who those who receive modern photon radiotherapy; and, among those who do receive C12, no statistical difference is observed between inoperable and partially resected tumors. Thus, definitive radiotherapy is identified as a valid treatment alternative, and extensive and morbid resections in patients with advanced ACC may need to be reconsidered.

    4. Disparities Research
      Elimination of cost-sharing and receipt of screening for colorectal and breast cancer

      Stacey A. Fedewa, Michael Goodman, W. Dana Flanders, Xuesong Han, Robert A. Smith, Elizabeth M. Ward, Chyke A. Doubeni, Ann Goding Sauer and Ahmedin Jemal

      Article first published online: 4 JUN 2015 | DOI: 10.1002/cncr.29494

      Overall, adjusted colorectal screening prevalence increased between 2008 and 2013 for low-income, least-educated, and Medicare-insured respondents but not in high-income, most-educated, and privately insured respondents. The increase in colorectal cancer screening prevalence between 2008 and 2013 among respondents with low socioeconomic status may in part reflect the removal of cost-sharing through the Patient Protection and Affordable Care Act.

    5. Disease Site

      Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma

      Franz O. Smith, Binglin Yue, Suroosh S. Marzban, Brooke L. Walls, Michael Carr, Ryan S. Jackson, Christopher A. Puleo, Tapan Padhya, C. Wayne Cruse, Ricardo J. Gonzalez, Amod A. Sarnaik, Michael J. Schell, Ronald C. DeConti, Jane L. Messina, Vernon K. Sondak and Jonathan S. Zager

      Article first published online: 2 JUN 2015 | DOI: 10.1002/cncr.29452

      In Merkel cell carcinoma, increasing primary tumor diameter and increasing tumor depth are independently predictive of a positive sentinel lymph node and disease-specific survival. Tumor depth should be routinely reported when primary Merkel cell carcinoma specimens are being evaluated histopathologically.

    6. Discipline

      Clinical Trials
      Estrogen and colorectal cancer incidence and mortality

      Sayeh Lavasani, Rowan T. Chlebowski, Ross L. Prentice, Ikuko Kato, Jean Wactawski-Wende, Karen C. Johnson, Alicia Young, Rebecca Rodabough, F. Allan Hubbell, Ali Mahinbakht and Michael S. Simon

      Article first published online: 2 JUN 2015 | DOI: 10.1002/cncr.29464

      According to the Women's Health Initiative randomized controlled clinical trial, estrogen use in postmenopausal women with prior hysterectomy does not influence the incidence of colorectal cancer or colorectal cancer deaths.

    7. Epidemiology
      You have full text access to this OnlineOpen article
      Universal tumor screening for lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers

      Jessica Ezzell Hunter, Jamilyn M. Zepp, Mari J. Gilmore, James V. Davis, Elizabeth J. Esterberg, Kristin R. Muessig, Susan K. Peterson, Sapna Syngal, Louise S. Acheson, Georgia L. Wiesner, Jacob A. Reiss and Katrina A.B. Goddard

      Article first published online: 2 JUN 2015 | DOI: 10.1002/cncr.29470

      In the current study, perspectives among patients newly diagnosed with colorectal cancer are assessed regarding universal tumor screening for Lynch syndrome. The majority of patients appear to have a positive attitude toward screening and endorse the benefits for themselves and their families, whereas potential barriers include concerns over the cost of additional genetic counseling and testing.

    8. Quality of Life
      Are lifestyle behavioral factors associated with health-related quality of life in long-term survivors of non-Hodgkin lymphoma?

      Denise J. Spector, Devon Noonan, Deborah K. Mayer, Habtamu Benecha, Sheryl Zimmerman and Sophia K. Smith

      Article first published online: 2 JUN 2015 | DOI: 10.1002/cncr.29490

      Healthy lifestyle behaviors appear to be related to better health-related quality of life, both mentally and physically, in long-term survivors of non-Hodgkin lymphoma. The majority of these individuals are not meeting American Cancer Society guidelines for health behaviors, which could impact their overall well-being and longevity.

  35. Editorial

    1. Prognostic factors and immunobiologic insights into Merkel cell carcinoma

      Dale Han and Jayasri G. Iyer

      Article first published online: 2 JUN 2015 | DOI: 10.1002/cncr.29453

      Merkel cell carcinoma is an aggressive cutaneous neuroendocrine cancer, and although the current staging system takes into account several prognostic features, further study is needed to better determine whether other clinicopathologic features are also predictive of survival. The discovery of the Merkel cell polyomavirus with persistently expressed viral epitopes and an understanding of the various immune evasion mechanisms in Merkel cell carcinoma tumors provide an exciting and unique opportunity for the development of rational immune therapies to improve patient outcomes for this biologically unique, virus-associated cancer.

  36. Original Articles

    1. Discipline

      Radiation Oncology
      Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer

      Lora S. Wang, Colin T. Murphy, Karen Ruth, Nicholas G. Zaorsky, Marc C. Smaldone, Mark L. Sobczak, Alexander Kutikov, Rosalia Viterbo and Eric M. Horwitz

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29472

      Obesity is an epidemic affecting greater than one-third of adults in the United States, and its incidence has more than doubled in the last 40 years. In the cohort of patients with prostate cancer in the current study, increasing body mass index appears to be associated with an increased risk of biochemical failure, distant metastases, and prostate cancer-specific and overall mortality in patients treated with dose-escalated intensity-modulated radiotherapy and daily image guidance.

    2. Disease Site

      Hepatobiliary Disease
      Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma

      Hui Wang, Ying Liu, Xiu Wang, Donghui Liu, Zhiqiang Sun, Chun Wang, Gang Jin, Beiguang Zhang and Shilong Yu

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29456

      The therapeutic potential of arsenic trioxide for the treatment of cancer has been accumulatively addressed. However, few randomized controlled studies have been conducted for the treatment of hepatocellular carcinoma with arsenic trioxide. In this article, a randomized controlled study is presented, and the efficacy and safety of adjuvant arsenic trioxide treatment in hepatocellular carcinoma patients receiving locoregional therapy are determined. The findings may provide valuable insights into the clinical use of adjuvant arsenic trioxide therapy for patients with hepatocellular carcinoma.

    3. Hematologic Malignancies
      Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia

      Christine M. Gronseth, Scott E. McElhone, Barry E. Storer, Kathleen A. Kroeger, Vicky Sandhu, Matthew L. Fero, Frederick R. Appelbaum, Elihu H. Estey and Min Fang

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29475

      Copy-neutral loss of heterozygosity is an independent prognostic factor for early disease recurrence in patients with acute myeloid leukemia. Genomic complexity revealed by chromosome genomic array testing conveys the same poor prognosis in these patients as did complex cytogenetics.

    4. Discipline

      Outcomes Research
      You have full text access to this OnlineOpen article
      Impact of aggressive management and palliative care on cancer costs in the final month of life

      Matthew C. Cheung, Craig C. Earle, Jagadish Rangrej, Thi H. Ho, Ning Liu, Lisa Barbera, Refik Saskin, Joan Porter, Soo Jin Seung and Nicole Mittmann

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29485

      Cancer patients who receive aggressive end-of-life care incur 43% higher costs than those managed nonaggressively; these costs are driven by a heavy dependence on acute institutional care. Palliative consultation may partially offset these costs by tempering the tendency toward aggressive management and offer resultant savings.

    5. Medical Oncology
      Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

      Karen L. Reckamp, Marianna Koczywas, Mihaela C. Cristea, Jonathan E. Dowell, He-Jing Wang, Brian K. Gardner, Ginger L. Milne, Robert A. Figlin, Michael C. Fishbein, Robert M. Elashoff and Steven M. Dubinett

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29480

      This randomized trial evaluates the efficacy of combined erlotinib and celecoxib in patients with advanced non-small cell lung cancer and builds on previous work that defined urinary prostaglandin E metabolite as a marker for activation of the cyclooxygenase 2 pathway, demonstrating an improvement in progression-free survival among those patients with elevated baseline levels. A benefit for patients with wild-type epidermal growth factor receptor (EGFR), a population that has limited benefit with EGFR tyrosine kinase inhibitor therapy, also is identified.

  37. Editorial

    1. Cyclooxygenase 2 inhibition in patients with non-small cell lung cancer: Is this still a valid target for therapy?

      Shirish M. Gadgeel

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29479

      In a randomized trial, the combination of the cyclooxygenase 2 (COX-2) inhibitor celecoxib with erlotinib demonstrated improved progression-free survival in patients with elevated baseline urinary prostaglandin E metabolite levels. Further studies are required to assess the usefulness of this biomarker to identify those patients with non-small cell lung cancer who are likely to benefit from COX-2 inhibitors.

  38. Original Articles

    1. Discipline

      Outcomes Research
      Chemotoxicity recurrence in older patients: Risk factors and effectiveness of preventive strategies—a prospective study

      Martine Extermann, Richard R. Reich and Marina Sehovic

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29423

      There are surprisingly few reports in the literature assessing the effectiveness of strategies to prevent recurrence of toxicity from chemotherapy in older patients with cancer. In the current study, the authors analyze correlates of treatment modifications and recurrence of severe toxicity and suggest pathways toward improvement.

    2. Disease Site

      Soft Tissue and Bone Sarcoma
      Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy—a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Global Network Study (EORTC 62072)

      Corneel Coens, Winette T. A. van der Graaf, Jean-Yves Blay, Sant P. Chawla, Ian Judson, Roberta Sanfilippo, Stephanie C. Manson, Rachel A. Hodge, Sandrine Marreaud, Judith B. Prins, Iwona Lugowska, Saskia Litière and Andrew Bottomley

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29426

      Although health-related quality of life is not improved by pazopanib, improved progression-free survival without impairment of health-related quality of life can be considered a meaningful result in patients with pretreated, metastatic soft tissue sarcoma. The toxicity profile of pazopanib is reflected in the patients’ self-reported symptoms but does not translate into significantly worse overall global health during treatment, because patients maintain role and social functioning.

  39. Editorial

    1. Patient-reported outcomes enhance understanding of the impact of pazopanib in soft tissue sarcoma

      Carolyn Gotay

      Article first published online: 29 MAY 2015 | DOI: 10.1002/cncr.29429

      The primary conclusion of this study—that increased progression-free survival is associated with more symptoms but not with compromised global health-related quality of life (global health status)—has important implications. A more fine-grained approach is necessary to understand more about why patients rate their global health status as they do and how they interpret and explain their symptom experience.

  40. Correspondence

    1. Reply to BRCA2-associated pancreatic cancer and current screening guidelines

      Jennifer K. Litton, Jeffrey H. Lee and Banu K. Arun

      Article first published online: 27 MAY 2015 | DOI: 10.1002/cncr.29446

  41. Commentary

    1. Cancer registry data: Engaging the clinician to improve quality

      Elliot A. Asare, Donna M. Gress, Frederick L. Greene and David P. Winchester

      Article first published online: 27 MAY 2015 | DOI: 10.1002/cncr.29483

      Cancer registry data items need to be updated to reflect current practice trends. Close collaboration between clinicians and registrars is needed to improve the quality of the data collected.

  42. Correspondence

    1. BRCA2-associated pancreatic cancer and current screening guidelines

      Pashtoon Murtaza Kasi, Katrina S. Pedersen and Robert R. McWilliams

      Article first published online: 27 MAY 2015 | DOI: 10.1002/cncr.29447

  43. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      You have full text access to this OnlineOpen article
      Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program

      Han-Mo Chiu, Sam Li-Sheng Chen, Amy Ming-Fang Yen, Sherry Yueh-Hsia Chiu, Jean Ching-Yuan Fann, Yi-Chia Lee, Shin-Liang Pan, Ming-Shiang Wu, Chao-Sheng Liao, Hsiu-Hsi Chen, Shin-Lan Koong and Shu-Ti Chiou

      Article first published online: 20 MAY 2015 | DOI: 10.1002/cncr.29462

      A significant reduction in colorectal cancer mortality resulting from fecal immunochemical testing is demonstrated by a large, population-based, nationwide service screening program with a maximum follow-up of 6 years. Although long-term follow-up of this nationwide service screening program is required, these findings are useful for convincing health decision makers that the continuous promotion of such a nationwide screening program is worthwhile.

  44. Editorial

    1. Where does it FIT?: The roles of fecal testing and colonoscopy in colorectal cancer screening

      Grace Clarke Hillyer and Alfred I. Neugut

      Article first published online: 20 MAY 2015 | DOI: 10.1002/cncr.29459

      Although colonoscopy is predominant among the selection of colorectal cancer screening tests, stool testing (particularly fecal immunochemical testing) has also carved out an important niche for itself. Its simplicity and low cost make it ideal for mass population screening both in the United States and abroad, and it is an alternative choice for those reluctant to undergo endoscopy.

  45. Correspondence

  46. Original Articles

    1. Discipline

      Cervical cancer screening and follow-up in 4 geographically diverse US health care systems, 1998 through 2007

      Sheila Weinmann, Andrew E. Williams, Aruna Kamineni, Diana S.M. Buist, Erin E. Masterson, Natasha K. Stout, Azadeh Stark, Tyler R. Ross, Christopher L. Owens, Terry S. Field and Chyke A. Doubeni

      Article first published online: 18 MAY 2015 | DOI: 10.1002/cncr.29445

      Over a 10-year period, with the adoption of new guidelines, Papanicolaou testing appears to have decreased, whereas human papillomavirus testing rates and the interval between Papanicolaou tests increased. The results of the current study suggest that these changes in cervical screening practices did not change the rates of detection of clinically significant lesions.

    2. Complementary Medicine
      A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus–induced prostate-specific antigen responses

      Przemyslaw Twardowski, Noriko Kanaya, Paul Frankel, Timothy Synold, Christopher Ruel, Sumanta K. Pal, Maribel Junqueira, Manisha Prajapati, Tina Moore, Pamela Tryon and Shiuan Chen

      Article first published online: 18 MAY 2015 | DOI: 10.1002/cncr.29421

      Therapy with white button mushroom (Agaricus bisporus) powder decreases prostate-specific antigen (PSA) levels in biochemically recurrent prostate cancer patients. In some cases, it also produces durable, complete PSA responses. Correlative analyses of both cytokines and myeloid-derived suppressor cells reveal significantly higher baseline levels of interleukin-15 and a decrease in the percentage of myeloid-derived suppressor cells after treatment in patients who have experienced PSA complete response.

    3. Disease Site

      Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme

      Young-Hoon Kim, Tackeun Kim, Jin-Deok Joo, Jung Ho Han, Yu Jung Kim, In Ah Kim, Chang-Ho Yun and Chae-Yong Kim

      Article first published online: 14 MAY 2015 | DOI: 10.1002/cncr.29439

      Levetiracetam may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy. A prospective randomized study may be indicated.

    4. Discipline

      Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer

      Manasi S. Shah, David R. Fogelman, Kanwal Pratap Singh Raghav, John V. Heymach, Hai T. Tran, Zhi-Qin Jiang, Scott Kopetz and Carrie R. Daniel

      Article first published online: 14 MAY 2015 | DOI: 10.1002/cncr.29440

      The joint contribution of chronic systemic inflammation and obesity to the survival of patients with metastatic colorectal cancer has not been reported previously. Although no association is observed for body mass index alone in the current study, obese patients with high serum marker levels at baseline experienced the highest risk of death in this cohort.

    5. Disease Site

      Genitourinary Disease
      Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases

      Jie-Fu Chen, Hao Ho, Jake Lichterman, Yi-Tsung Lu, Yang Zhang, Mitch A. Garcia, Shang-Fu Chen, An-Jou Liang, Elisabeth Hodara, Haiyen E. Zhau, Shuang Hou, Rafi S. Ahmed, Daniel J. Luthringer, Jiaoti Huang, Ker-Chau Li, Leland W. K. Chung, Zunfu Ke, Hsian-Rong Tseng and Edwin M. Posadas

      Article first published online: 14 MAY 2015 | DOI: 10.1002/cncr.29455

      In this observational study, the authors use NanoVelcro chips to isolate circulating tumor cells (CTCs) from patients with prostate cancer and generate cell images appropriate for histopathological analysis and nuclear size measurement. In doing so, the authors identify a CTC subset of very small nuclear CTCs that exhibits significant correlation with the presence of visceral metastases and can be explored as a potential biomarker for this lethal progression in patients with prostate cancer.

  47. Editorial

    1. Circulating tumor cells in prostate cancer: Does (nuclear) size matter?

      Sumanta K. Pal, Neeraj Agarwal and Jeremy O. Jones

      Article first published online: 14 MAY 2015 | DOI: 10.1002/cncr.29454

      The enumeration of circulating tumor cells has established prognostic value in patients with metastatic castration-resistant prostate cancer. Herein, the authors comment on a study examining the usefulness of evaluating the nuclear size of circulating tumor cells across various stages of prostate cancer.

  48. Original Articles

    1. Discipline

      Psychosocial Oncology
      Male-female patient differences in the association between end-of-life discussions and receipt of intensive care near death

      Rashmi K. Sharma, Holly G. Prigerson, Frank J. Penedo and Paul K. Maciejewski

      Article first published online: 14 MAY 2015 | DOI: 10.1002/cncr.29417

      End-of-life discussions dramatically decrease the likelihood of intensive care unit care near death for male patients but not for female patients. Efforts to promote end-of-life discussions between male patients and their oncologists are indicated.

    2. Clinical Trials
      The effect of oncologists' exercise recommendations on the level of exercise and quality of life in survivors of breast and colorectal cancer: A randomized controlled trial

      Ji-Hye Park, Junga Lee, Minsuk Oh, Hyuna Park, Jisuk Chae, Dong-Il Kim, Mi Kyung Lee, Yong Jin Yoon, Chul Won Lee, Seho Park, Lee W. Jones, Nam Kyu Kim, Seung Il Kim and Justin Y. Jeon

      Article first published online: 12 MAY 2015 | DOI: 10.1002/cncr.29400

      An oncologist's exercise recommendation may not be enough to increase exercise participation among cancer survivors. Providing an exercise motivation package in addition to the oncologist's exercise recommendation to increase the level of exercise among survivors of breast and colorectal cancer should be considered.

  49. Erratum

    1. You have free access to this content
  50. Communications

    1. You have free access to this content
      A Titan exits stage left: Summary of the Waun Ki Hong Festschrift

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29410

      On August 15, 2014, at The University of Texas MD Anderson Cancer Center in Houston, Dr. Fadlo Khuri, along with co-chairs Drs. James Abbruzzese, Patrick Hwu, Roy Herbst, and Scott Lippman, chaired a Festschrift celebrating the lifetime of accomplishments of Dr. Waun Ki Hong. A series of lectures celebrating Dr. Hong's legacy ensued, highlighting his accomplishments in the areas of induction chemotherapy, organ preservation, head and neck biology, carcinogenesis, and chemoprevention, as well as his leadership in the biological interrogation of biomarker-driven pathways in lung and head and neck cancer and his transformation of the culture of mentorship and multidisciplinary science at The University of Texas MD Anderson Cancer Center.

    2. You have free access to this content
      Honoring Dr. Waun Ki Hong, a cancer pioneer and visionary: On the occasion of his Festschrift, August 14, 2014

      Howard K. Koh

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29411

      At a special dinner, the keynote speaker, Dr. Howard H. Koh, the immediate past U.S. Assistant Secretary for Health gave a speech honoring Dr. Waun Ki Hong on the occasion of his Festschrift on August 14, 2014.

  51. Original Articles

    1. Disease Site

      Head and Neck Disease
      Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma

      Edwin P. Hui, Brigette B. Y. Ma, K. C. Allen Chan, Charles M. L. Chan, Cesar S. C. Wong, Ka Fai To, Anthony W. H. Chan, Stewart Y. Tung, Wai-Tong Ng, Ashley C. Cheng, Victor H. F. Lee, Stephen L. Chan, Herbert H. F. Loong, Michael K. M. Kam, Sing-Fai Leung, Rosalie Ho, Frankie Mo, Roger K. C. Ngan and Anthony T. C. Chan

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29413

      In a prospective biomarker study of patients with nasopharyngeal cancer, plasma Epstein-Barr virus DNA is validated as the most significant prognostic biomarker for use in selecting high-risk patients for adjuvant therapy. The ERCC1 C118T genotype may help to identify a favorable subgroup of patients (approximately 7%) with plasma Epstein-Barr virus DNA-negative nasopharyngeal cancer who have an excellent prognosis and can be spared the toxicities of further therapy.

    2. Discipline

      Disparities Research
      Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first-degree relatives

      Roshan Bastani, Beth A. Glenn, Annette E. Maxwell, Patricia A. Ganz, Cynthia M. Mojica, Susan Alber, Catherine M. Crespi and L. Cindy Chang

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29403

      First-degree relatives of colorectal cancer cases are at an elevated risk of developing the disease but remain underscreened. An ethnically targeted intervention has been found to successfully increase screening for colorectal cancer in this group.

  52. Editorial

    1. Editorial

      Individualizing treatment for patients with nasopharyngeal cancer

      Wendy Hara and Quynh-Thu Le

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29418

      In this issue, Dr. Hui and colleagues report the largest multi-institutional, prospective trial to date validating circulating Epstein-Barr virus DNA as a prognostic biomarker for patients with nasopharyngeal cancer after chemoradiotherapy. The ERCC1 C118T single nucleotide polymorphism genotype may also be a potential second biomarker for future investigation.

  53. Original Articles

    1. Discipline

      Translational Research
      Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry

      Yusheng Lu, Haiyan Liang, Ting Yu, Jingjing Xie, Shuming Chen, Haiyan Dong, Patrick J. Sinko, Shu Lian, Jianguo Xu, Jichuang Wang, Suhong Yu, Jingwei Shao, Bo Yuan, Lie Wang and Lee Jia

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29444

      Circulating tumor cells not only might be used as real-time markers for predicting disease progression and survival for patients with metastatic and possibly even early-stage cancer but also might become a treatment target for the prevention of tumor metastasis. This article describes a novel method for the isolation and characterization of living circulating tumor cells. Isolated living circulating tumor cells are suitable for cell culture studies and will allow detailed molecular and eventually functional characterization, and this will determine the clinical value of circulating tumor cells for targeted and personalized medicine.

    2. Supportive Care
      Psychometric properties of an Australian supportive care needs assessment tool for Indigenous patients with cancer

      Gail Garvey, Vanessa L. Beesley, Monika Janda, Peter K. O'Rourke, Vincent Y.F. He, Anna L. Hawkes, Jacinta K. Elston, Adele C. Green, Joan Cunningham and Patricia C. Valery

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29433

      To date, insufficient attention has been given to the psychosocial needs of Indigenous patients with cancer. This newly developed and psychometrically tested tool is culturally relevant and sensitive to the needs of Indigenous Australians and can assist in addressing disparities with regard to support, information, services, and resource allocation.

  54. Commentary

    1. Business as usual is not acceptable

      K. Michael Cummings, James W. Gustafson Jr., David J. Sales, Fadlo R. Khuri and Graham W. Warren

      Article first published online: 6 MAY 2015 | DOI: 10.1002/cncr.29442

      It is time for the cigarette industry to be held accountable for the consequences of manufacturing and promoting a product that causes so much disease and death. Punitive damage awards in tobacco litigation are an important way to make the cigarette companies recognize that Business as usual is not acceptable.

  55. Original Articles

    1. Disease Site

      Breast Disease
      5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial

      Nina D. Wagner-Johnston, Jeff A. Sloan, Heshan Liu, Ann E. Kearns, Stephanie L. Hines, Suneetha Puttabasavaiah, Shaker R. Dakhil, Jacqueline M. Lafky, Edith A. Perez and Charles L. Loprinzi

      Article first published online: 30 APR 2015 | DOI: 10.1002/cncr.29327

      At 5 years of follow-up of this randomized controlled trial, immediate treatment with ZA prevented bone loss compared with delayed treatment in postmenopausal women receiving letrozole for breast cancer. Differences between the treatment arms with regard to the development of osteoporosis or fractures were not statistically significant.

    2. Hematologic Malignancies
      Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes

      Sameer A. Parikh, Jose F. Leis, Kari G. Chaffee, Timothy G. Call, Curtis A. Hanson, Wei Ding, Asher A. Chanan-Khan, Deborah Bowen, Michael Conte, Susan Schwager, Susan L. Slager, Daniel L. Van Dyke, Diane F. Jelinek, Neil E. Kay and Tait D. Shanafelt

      Article first published online: 30 APR 2015 | DOI: 10.1002/cncr.29438

      This large, retrospective cohort study of approximately 1500 patients with chronic lymphocytic leukemia (CLL) indicates that approximately 25% of patients with CLL have hypogammaglobulinemia at the time of their initial diagnosis; and, among those who have normal serum immunoglobulin G levels at diagnosis, approximately 25% develop hypogammaglobulinemia over the next 10 years without the receipt of CLL therapy. Although the presence of hypogammaglobulinemia at initial diagnosis predicts the time to first CLL therapy, it does not have an impact on overall survival.

    3. Discipline

      Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study

      James D. Murphy, Grace L. Ma, Joel M. Baumgartner, Lisa Madlensky, Adam M. Burgoyne, Chih-Min Tang, Maria Elena Martinez and Jason K. Sicklick

      Article first published online: 30 APR 2015 | DOI: 10.1002/cncr.29434

      This is the first population-based study to characterize the associations and temporal relations between gastrointestinal stromal tumors and other cancers by both site and histological type. These results may carry important clinical implications for future cancer screening and treatment strategies.

  56. Editorials

    1. And the GIST is: When one has a GIST, think of an association!

      Constantine A. Stratakis

      Article first published online: 30 APR 2015 | DOI: 10.1002/cncr.29435

      Patients with gastrointestinal stromal tumors have been found to have other cancers more frequently than expected by chance in a population study. The findings are supportive of a genetic predisposition being more frequent in gastrointestinal stromal tumors, although other reasons cannot be excluded; clinicians need to bear in mind the possible association of a gastrointestinal stromal tumor with another primary cancer.

  57. Correspondence

  58. Original Articles

    1. Discipline

      Symptom Control and Palliative Care
      Health care utilization and end-of-life care for older patients with acute myeloid leukemia

      Areej R. El-Jawahri, Gregory A. Abel, David P. Steensma, Thomas W. LeBlanc, Amir T. Fathi, Timothy A. Graubert, Daniel J. DeAngelo, Martha Wadleigh, Karen K. Ballen, Julia E. Foster, Eyal C. Attar, Philip C. Amrein, Andrew M. Brunner, Richard M. Stone and Jennifer S. Temel

      Article first published online: 29 APR 2015 | DOI: 10.1002/cncr.29430

      Older patients with acute myeloid leukemia spend a significant portion of their life after diagnosis in the hospital or clinic, and they are likely to die in the hospital. Despite their poor prognosis, older patients with acute myeloid leukemia infrequently receive palliative care or hospice services.

  59. Correspondence

    1. Age-related differences in quality of life among patients with diffuse large B-cell lymphoma

      Simone Oerlemans, Marten R. Nijziel and Lonneke V. van de Poll-Franse

      Article first published online: 29 APR 2015 | DOI: 10.1002/cncr.29427

  60. Editorials

    1. The graceful exit or reluctant demise of the older adult with acute myeloid leukemia

      Mikkael A. Sekeres and Aaron T. Gerds

      Article first published online: 29 APR 2015 | DOI: 10.1002/cncr.29428

      Older adults with acute myeloid leukemia should be better prepared for the difficult realities of their disease, and clinicians should adjust their optimism about the potential benefits of induction chemotherapy and practice under the assumption that patients will relapse or that therapy will fail. These patients and their families will then be ready for the health care burden they are about to endure and will be much more open to the suggestion of palliative approaches or hospice when the time comes, recognizing it as part of the natural course of events.

  61. Original Articles

    1. Discipline

      Outcomes Research
      Use and impact of intermittent versus continuous systemic treatment strategies in metastatic colorectal cancer in routine practice

      Amin Kay, Lingsong Yun, Nathan Taback and Monika K. Krzyzanowska

      Article first published online: 29 APR 2015 | DOI: 10.1002/cncr.29412

      Intermittent treatment strategies are being used in routine practice for patients with metastatic colorectal cancer. The frequency of breaks and the impact on survival and toxicity vary with the type of first-line chemotherapy.

    2. Disease Site

      Genitourinary Disease
      Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease

      Florence K. Keane, Ming-Hui Chen, Danjie Zhang, Brian J. Moran, Michelle H. Braccioforte and Anthony V. D'Amico

      Article first published online: 29 APR 2015 | DOI: 10.1002/cncr.29420

      Short-course neoadjuvant androgen deprivation therapy (ADT) does not reduce the risk of prostate cancer-specific mortality (PCSM) in men undergoing brachytherapy for favorable intermediate-risk prostate cancer and therefore should not be considered standard. It does appear to be superior in reducing PCSM risk when compared with neoadjuvant radiotherapy in men with unfavorable intermediate-risk prostate cancer, making short-course neoadjuvant ADT and brachytherapy a preferred treatment option in these men.


  1. 1 - 100
  2. 101 - 128